Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.56 |
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992447 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL1992449 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL11086941 | 0.86 | CTSS (0.47) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3186812 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL5742936 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL5740500 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL1998569 | 0.83 | KMT2A (0.47) | MAPTATM | |
| SCHEMBL1998567 | 0.83 | KMT2A (0.47) | MAPTATM | |
| SCHEMBL7273399 | 0.83 | GABRB1 (0.52) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL11852061 | 0.82 | CTSS (0.45) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4614797-A | Cephalosporin hydroxamic acids | SHIONOGI & CO., LTD. (JP) | 1986-09-30 | — | — | US | claimed |
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | THE UNIVERSITY OF KANSAS | 2016-12-01 | — | — | US | disclosed |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015095780-A1 | TOLL-LIKE RECEPTOR 8 AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102822175-A | 5, 5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2012-12-12 | — | — | CN | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0738265-A1 | TAXANE DERIVATIVES | PHARMACIA S.p.A. (IT) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996014308-A1 | TAXANE DERIVATIVES | PHARMACIA S.P.A. (IT) | 1996-05-17 | — | — | WO | disclosed |
| EP-0675899-A4 | NOVEL INHIBITORS OF FACTOR Xa. | CORVAS INT INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0675899-A1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994013693-A1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | CTSK 749/4885CTSS 1244/4885CTSL 1425/4885 |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | CTSK 4461/4885CTSS 3941/4885CTSL 3134/4885 |
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | CTSK 4673/4885CTSS 4320/4885CTSL 3343/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | CTSK 749/4885CTSS 1244/4885CTSL 1425/4885 |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | TLR8, TLR7, TLR1 | CTSK 4673/4885CTSS 4320/4885CTSL 3343/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | CTSK 4461/4885CTSS 3941/4885CTSL 3134/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | CTSK 305/4885CTSS 948/4885CTSL 648/4885 |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, LIPC, LDHB | CTSK 2332/4885CTSS 2878/4885CTSL 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.